Overview of Codeine Phosphate 10%

Property	Description
Active ingredient	Codeine (as Codeine Phosphate)
Form	Oral Solution (Linctus), Tablet, Injection
Pharmacological class	Opioid Analgesic, Antitussive
General purpose	Pain relief, Cough suppression
Origin	Semi-synthetic (derived from opium poppy alkaloids)

What Type of Medicine is Codeine Phosphate and What is Its Purpose?

Codeine Phosphate 10% is a medicinal preparation whose active component, Codeine, is a weak opioid analgesic and a narcotic analgesic. Its general therapeutic purpose is the relief of mild to moderate acute pain and the suppression of a nonproductive cough. The preparation's name indicates the specific 10% concentration of the active substance, a strength utilized for its therapeutic effects.

The substance is a phenanthrene alkaloid that works by modulating signals in the central nervous system (CNS). While it is naturally derived from the opium poppy (Papaver somniferum), it is typically manufactured as a semi-synthetic derivative of morphine in commercial practice. Codeine is used for both pain management and cough suppression.

Composition and The 10% Preparation

The primary active ingredient is Codeine, prepared as the salt Codeine Phosphate to ensure enhanced solubility and stability. This specific 10% preparation is frequently an Oral Solution (Linctus), which is a differentiating factor from standard tablet formulations, positioning it for patient groups who require an easily swallowed liquid form. This medicine is generally a single-ingredient product, designed for oral administration. Codeine is a controlled substance due to its analgesic properties.

The Unique Prodrug Action (Basic Concept)

Codeine is fundamentally a prodrug, meaning the molecule must be chemically altered, or metabolized, by the body before it becomes fully active. Its therapeutic function relies on the metabolic process called O-demethylation, which converts Codeine into its primary active metabolite, morphine, via the CYP2D6 enzyme in the liver. This reliance on metabolic conversion is a key characteristic that influences individual patient outcomes and differentiates Codeine from analgesics that are active immediately upon administration.

Regulatory References

What side effects are possible with Codeine Phosphate 10%?

Possible Side Effects and Safety Information

The safety profile of Codeine Phosphate is defined by a range of officially documented adverse reactions and strict safety constraints outlined in regulatory labeling. The most frequently reported adverse reactions typically involve the Central Nervous System and the Gastrointestinal System.

General Adverse Reaction Profile

Adverse effects commonly documented in regulatory sources include drowsiness, lightheadedness, dizziness, and sedation. Gastrointestinal reactions frequently observed include nausea, vomiting, and constipation. Other documented effects include shortness of breath, sweating, pruritus (itching), and mood alterations such as euphoria or dysphoria.

Serious Adverse Reactions

Official regulatory warnings emphasize the potential for severe, life-threatening risks, including Respiratory Depression, which requires monitoring, particularly upon treatment initiation or following a dose increase. The risks of Addiction, Abuse, and Misuse are explicitly documented. Other serious adverse reactions include Severe Hypotension, the potential for Adrenal Insufficiency, and Serotonin Syndrome when used with certain other medications.

Population-Specific Safety Considerations

The medicine is contraindicated in children younger than 12 years of age, and in adolescents younger than 18 years following tonsillectomy and/or adenoidectomy, due to concerns over metabolism. Prolonged use during pregnancy can result in the Neonatal Opioid Withdrawal Syndrome (NOWS), and breastfeeding is not recommended due to the risk of exposing the infant to the active metabolite.

Safety Restrictions

Codeine is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, and known or suspected gastrointestinal obstruction, including paralytic ileus.

Overdose and Emergency Response

The official regulatory documentation for Codeine Phosphate describes overdose as a potentially life-threatening event primarily defined by profound central nervous system and respiratory depression.

System Affected	Documented Clinical Manifestations
Respiratory	Slow, shallow, or absent breathing (respiratory depression)
CNS	Extreme drowsiness (somnolence), stupor, and eventual coma
Systemic	Pinpoint pupils, low blood pressure (hypotension), and muscle flaccidity

Severe manifestations may include pulmonary edema and potentially fatal outcomes if the respiratory depression is not immediately reversed. Immediate medical attention is required for any suspected overdose. Seek emergency help right away if signs of severe toxicity—such as breathing difficulties, unresponsiveness, or profound confusion—are observed.

Management involves the reestablishment of a protected airway and the use of an opioid antagonist, such as Naloxone, as the necessary intervention. Regulatory agencies highlight specific risks: Accidental ingestion by a child can be fatal, and certain individuals, such as ultra-rapid metabolizers, face an increased risk of severe toxicity. Close hospital monitoring of vital signs is typically required.

Therapeutic Uses of Codeine Phosphate 10%

What Codeine Phosphate 10% Treats: Main Uses and Benefits

Codeine Phosphate is generally considered for its therapeutic utility in addressing several distressing symptom domains. The medication is commonly used to help manage acute pain of mild to moderate intensity and is relevant for easing symptoms related to the persistent cough reflex.

The primary use of the medication is to provide symptomatic relief across conditions characterized by periods of heightened symptoms, including when pain symptoms require additional management beyond non-opioid options, the irritating, non-productive (dry) cough reflex, and symptoms related to excessive bowel motility in specific clinical settings. The medication is commonly applied in scenarios where short-term symptomatic assistance is needed, such as during post-procedural discomfort or when symptoms that interfere with daily functioning, such as a persistent dry cough, are present.

“The primary benefit is the provision of symptomatic relief from pain, which supports general well-being during symptomatic phases.”

This supportive action helps ease the overall symptom burden, supporting patients during difficult episodes by easing distress.

Quick Fact: Symptomatic Support for Pain and Cough

This medication is commonly used to help manage symptoms related to physical discomfort (mild to moderate pain) and is relevant for easing the symptoms of a persistent, non-productive cough reflex.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Codeine Phosphate 10% eligibility is strictly defined by regulatory documents based on age, metabolic profile, and specific existing medical conditions.

Populations for Whom Use is Contraindicated

The medicine is prohibited for use in children under 12 years of age for any indication. It is also contraindicated in adolescents under 18 years following tonsillectomy or adenoidectomy. Individuals of any age known to be CYP2D6 ultra-rapid metabolizers must not use this medicine due to the risk of toxicity. Absolute exclusions also apply to breastfeeding mothers and patients with significant respiratory depression, acute or severe bronchial asthma, hypercarbia, or confirmed paralytic ileus.

Restricted and Conditional Use

Use is restricted in adolescents aged 12 to 18 years, where it is indicated only for short-term moderate pain that has not been relieved by non-opioid treatments. The medicine requires caution and close monitoring in elderly patients and in those with severe hepatic or renal impairment. Conditional use is also specified for patients with chronic pulmonary disease, head injury, or conditions causing increased intracranial pressure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Codeine Phosphate's interaction profile is characterized by two main pharmacological considerations: additive central nervous system (CNS) depression and metabolic pathway effects.

Significant Drug Classes and Substances

Interaction Domain	Mechanism and Implication	Official Regulatory Constraint
CNS Depressants (e.g., alcohol, benzodiazepines, other opioid analgesics, gabapentinoids, sedatives, hypnotics, antihistamines)	Risk of enhanced sedation and respiratory depression.	Use the lowest effective dose for the shortest duration; close monitoring is required.
Monoamine Oxidase Inhibitors (MAOIs) (e.g., isocarboxazid, phenelzine, tranylcypromine)	Potential for severe, potentially fatal reactions.	Concomitant use is avoided and must not be used within two weeks of MAOI discontinuation.
CYP2D6 Inhibitors (e.g., quinidine)	Decrease the metabolic conversion of codeine to the active metabolite, morphine.	Impairs or significantly reduces the expected analgesic effect of codeine.
Gastrointestinal Motility Agents (e.g., metoclopramide, domperidone)	Codeine antagonizes the prokinetic effect.	May counteract the intended therapeutic action of the prokinetic agent.

Population-Specific Constraint

Codeine is contraindicated in patients who are known or suspected to be CYP2D6 ultra-rapid metabolizers, particularly in children under 12 years of age, due to the rapid conversion to morphine, which increases the risk of life-threatening respiratory depression.

Mechanism of Action

Codeine is a prodrug that exerts its primary effects following metabolic conversion to the active opioid, morphine, predominantly in the liver. This O-demethylation is catalyzed by the cytochrome P450 isoenzyme CYP2D6.

Morphine acts as an agonist at mu-opioid receptors (MOR) located primarily in the central nervous system, including the brain and spinal cord, and the gastrointestinal tract. MOR are G-protein-coupled receptors (GPCRs) coupled to inhibitory Gi proteins.

Activation of MOR initiates an intracellular cascade that includes: inhibition of adenylyl cyclase, leading to a decrease in intracellular cyclic AMP (cAMP) levels; promotion of potassium efflux via G-protein-coupled inwardly-rectifying potassium (GIRK) channels, causing neuronal hyperpolarization; and inhibition of voltage-gated calcium channels, leading to a decrease in calcium influx.

These cellular actions result in the presynaptic inhibition of neurotransmitter release, including substance P and other pronociceptive mediators, and postsynaptic inhibition of neuronal excitability. The overall system-level physiological consequence includes the modulated transmission of afferent signals within the spinal cord and altered excitability within the medullary cough center and the enteric nervous system, affecting intestinal motility.

Dosage and Administration Information

Administration Route and Preparation

The administration of Codeine Phosphate follows standard protocols regarding route, dose, frequency, and duration. The medicine is primarily administered via the oral route as a tablet or solution, though parenteral forms are utilized in supervised clinical settings. When using the oral solution, accurate measurement of the prescribed volume requires a calibrated measuring device; household utensils should not be used, ensuring the correct dose is taken. The drug may be taken with or without food, as its absorption is not significantly affected by meals.

Dosing Schedule and Duration

The standard adult regimen for acute symptoms is structured for intermittent use, meaning it is taken as needed (PRN), rather than on a continuous schedule. Dosing is typically repeated every 4 to 6 hours, with single doses generally ranging from 15 mg to 60 mg. Treatment is generally initiated at the lowest effective dosage and overall use is constrained to the shortest possible duration. For acute use, total treatment length is generally limited to a maximum of 3 days.

Special Population Adjustments

Dose adjustments are typically considered for certain patient groups. For older adults, dose selection is cautious, typically starting at the low end of the therapeutic range. Patients with hepatic or renal impairment generally require a reduced initial dose or an extended dosing interval to account for altered metabolism and clearance. If the medicine is discontinued after prolonged use, the dose should be tapered gradually to avoid abrupt cessation effects.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Codeine Phosphate 10%

Evidence for Pain Relief (Mild to Moderate Acute Pain)

Research exploring Codeine Phosphate has been studied for conditions characterized by outcomes related to physical discomfort, specifically mild to moderate acute pain. These investigations primarily use Randomized Controlled Trials (RCTs), where the medicine is often evaluated in combination with non-opioid pain relievers. Studies monitored patient-reported outcomes describing perceived discomfort. Trials reported that the pain levels recorded in the codeine group were measured differently compared to the placebo group. However, when research examined codeine as a single agent, the findings were mixed across various acute pain types. The degree of effect measured in studies may be highly variable among individuals due to natural differences in how the body processes the medicine.

Evidence for Nonproductive Cough Suppression

Codeine was studied for its effect on outcomes linked to inflammatory or irritative states associated with a persistent, nonproductive cough. Research explored short-term symptom changes, primarily using double-blind RCTs that measured objective outcomes like cough frequency. Older studies described measured changes in cough severity and frequency in the observed populations. However, for the more common, episodic or acute changes, some systematic reviews indicate that the certainty remains low, with findings often describing results that were similar to placebo.

Key Research Gaps and Uncertainties

The majority of research focuses on short-term or episodic symptom patterns, and studies have follow-up durations that were limited to a few days or weeks. Long-term effects are not fully established by prospective clinical trials. Furthermore, the patient-reported outcomes describing perceived discomfort is highly variable because the pattern of measured effect is known to be dependent on the individual's metabolic ability to convert the drug. Regulatory bodies have identified a lack of robust evidence for research in certain pediatric populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Codeine Phosphate 10% (FAQ)

Q: Is Codeine Phosphate 10% the same as just Codeine?

Codeine Phosphate contains the active pain-relieving ingredient, Codeine. The term 'Phosphate' indicates that an inactive salt component has been added. Official documents explain that this chemical modification is done to improve the drug's overall solubility and stability, which is often necessary when creating liquid solutions.

Q: Why is this form called '10%'?

The '10%' in the product name typically refers to the concentration of the active ingredient, Codeine Phosphate, within the total preparation. This is a common way for regulatory bodies to identify the specific strength of a medicine, especially for oral liquid solutions where the concentration can vary.

Q: How long do the effects of Codeine Phosphate 10% typically last?

Pharmacokinetic data summarized in official documents indicates that the average duration of the drug's effect is approximately four hours. This is consistent with the standard dosing schedule for acute pain, which often describes administration every 4 to 6 hours.

Q: What is the risk of becoming dependent on Codeine Phosphate 10%?

Regulatory sources clearly state that the prolonged use of opioid medicines, including codeine, may lead to physical dependence. Physical dependence means the body has become accustomed to the drug's presence. Official guidance suggests that the dose should be gradually reduced, or tapered, after extended use; this process is intended to help manage potential effects upon stopping use.

Q: Does Codeine Phosphate 10% show up on standard drug tests?

Yes, as codeine is an opiate (a natural type of opioid), it is detectable on standard opioid screening tests, typically using urine samples. Because the body converts codeine into its active form, morphine, the presence of these substances may result in a positive screening.

Q: Are headaches a potential side effect of Codeine Phosphate 10%?

Headache is included in the list of reported side effects found in the official drug information for codeine-containing products. Like all medicines, individual experiences with side effects can vary.

Q: Is it possible to have an allergic reaction to Codeine Phosphate 10%?

Official drug information contains warnings about the potential for severe allergic reactions to the medicine. Official documents warn that signs of a severe allergic reaction may be seen, which requires immediate medical attention.

Q: Do official documents mention any effects of Codeine Phosphate 10% on mood?

Yes, official regulatory documents list specific mood changes in the general adverse reaction profile. These documented effects include both euphoria (a feeling of intense well-being) and dysphoria (a state of general unease or dissatisfaction).

Q: Why do some cough medicines contain codeine?

Codeine is officially classified and recognized as an antitussive agent, which means it is intended to help suppress a cough. It achieves this effect by modulating activity in the part of the central nervous system that controls the cough reflex.

Q: Are there documented interactions with herbal supplements?

Official sources caution that certain nonprescription and herbal products may interact with codeine. Specific examples mentioned in regulatory information include St. John's wort and tryptophan, which may affect how the drug works or increase the risk of certain side effects.

Q: Is Codeine Phosphate 10% appropriate for severe pain?

The official indication, according to regulatory bodies, is for the relief of mild to moderate acute pain. It is not indicated or described for the management of severe pain, which typically requires a different classification of pain reliever.

Q: Can Codeine Phosphate 10% be used with other cough and cold medicines?

Official information describes a need for awareness when combining codeine with other medicines that cause central nervous system (CNS) depression, including many common cough and cold remedies. Regulatory warnings specify that combining CNS depressants can enhance sedation and increase the risk of respiratory depression. Official warnings specify that combining CNS depressants may be avoided due to the increased risks described.

Q: Can Codeine Phosphate 10% be used for nerve pain?

Official documentation indicates codeine is used for general mild to moderate acute pain relief. However, regulatory authorities do not typically list 'nerve pain' (neuropathic pain) as a specific or recommended indication.

Q: Why is a prescription needed for Codeine Phosphate 10% in many places?

A prescription is required because codeine is internationally classified as a controlled substance (opioid/narcotic) due to its potential for abuse, addiction, and misuse. Prescription control is a regulatory measure used to help manage and mitigate these recognized public health risks.

Q: Does the efficacy of Codeine Phosphate 10% change over time?

Official labeling for long-term opioid use warns about the potential for tolerance to develop. Tolerance means the body's response to the drug may decrease over time. For this reason, official guidance emphasizes limiting treatment to the shortest possible duration.

Q: What should someone do if they suspect an overdose of Codeine Phosphate 10%?

Official guidance notes that in the event of suspected overdose, seeking emergency medical help is required. Symptoms of overdose may include slow or shallow breathing, extreme drowsiness, limp muscles, and an inability to wake up.

Q: Is it considered safe to use Codeine Phosphate 10% for dental pain?

Codeine is indicated for general relief of mild to moderate acute pain, which can include certain cases of dental pain. However, some official reviews note that other pain relievers may be used or evaluated for this specific type of acute pain.

Q: What are the official guidelines regarding the use of Codeine Phosphate 10% in patients with breathing problems?

The medicine is contraindicated (prohibited) for patients with significant respiratory depression, acute or severe bronchial asthma, and related conditions. For patients with other chronic pulmonary diseases, regulatory guidance requires close monitoring due to the risk of severe respiratory depression.

Q: Are there genetic factors that affect how Codeine Phosphate 10% works?

Yes, official warnings highlight that genetic factors relating to the CYP2D6 enzyme affect how the body converts codeine into its active form, morphine. Patients with certain genetic variations (ultra-rapid or poor metabolizers) may experience increased toxicity or ineffective pain relief, respectively.

Q: Is there a maximum time frame for using Codeine Phosphate 10% according to official guidance?

Official guidance mandates that the drug be used for the shortest possible duration necessary to treat the pain. For short-term acute pain relief, some national guidelines restrict the total treatment length to a maximum of three days.

Q: What research is available on Codeine Phosphate 10% effectiveness in combination therapies?

Official regulatory-backed reviews on codeine often focus on its use in combination therapies, such as when it is paired with non-opioid pain relievers. This body of evidence indicates that the combination medicines can provide important clinical pain relief in the immediate term.

How should Codeine Phosphate 10% be stored and disposed of?

Official Storage and Disposal Requirements

Codeine Phosphate is a controlled substance and must be stored securely to prevent theft, misuse, or accidental ingestion, particularly by children. Official regulatory documents specify the following requirements for storage, handling, and final disposition:

Storage and Handling

Requirement	Constraint
Temperature/Environment	Store at room temperature, away from excess heat and excess moisture. Do not store in the bathroom.
Security	Keep in the original, tightly closed container in a safe, secured, and locked location. Must be kept out of the sight and reach of children.
Stability	Protection from excess heat and moisture is required to maintain product integrity.

Disposal Instructions

For unused medication, the preferred method of disposal is to utilize a government-authorized drug take-back program or mail-back service. If these options are unavailable, regulatory instructions permit mixing the product (without crushing pills) with an unappealing substance, such as dirt or used coffee grounds. The mixture must then be sealed in a plastic bag and placed in the household trash. Patients should check the official labeling for product-specific instructions regarding toilet flushing of certain opioids.

Codeine Phosphate 10%